JP2023511376A5 - - Google Patents

Info

Publication number
JP2023511376A5
JP2023511376A5 JP2022544309A JP2022544309A JP2023511376A5 JP 2023511376 A5 JP2023511376 A5 JP 2023511376A5 JP 2022544309 A JP2022544309 A JP 2022544309A JP 2022544309 A JP2022544309 A JP 2022544309A JP 2023511376 A5 JP2023511376 A5 JP 2023511376A5
Authority
JP
Japan
Prior art keywords
domain
substitutions
heterodimer protein
protein according
residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022544309A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023511376A (ja
JP7710450B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2021/073347 external-priority patent/WO2021148006A1/en
Publication of JP2023511376A publication Critical patent/JP2023511376A/ja
Publication of JP2023511376A5 publication Critical patent/JP2023511376A5/ja
Priority to JP2025114854A priority Critical patent/JP2025160226A/ja
Application granted granted Critical
Publication of JP7710450B2 publication Critical patent/JP7710450B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022544309A 2020-01-23 2021-01-22 Ｆｃ変異を有するヘテロダイマータンパク質 Active JP7710450B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025114854A JP2025160226A (ja) 2020-01-23 2025-07-08 Ｆｃ変異を有するヘテロダイマータンパク質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/073960 2020-01-23
CN2020073960 2020-01-23
PCT/CN2021/073347 WO2021148006A1 (en) 2020-01-23 2021-01-22 Heterodimeric proteins with fc mutations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025114854A Division JP2025160226A (ja) 2020-01-23 2025-07-08 Ｆｃ変異を有するヘテロダイマータンパク質

Publications (3)

Publication Number Publication Date
JP2023511376A JP2023511376A (ja) 2023-03-17
JP2023511376A5 true JP2023511376A5 (https=) 2025-04-21
JP7710450B2 JP7710450B2 (ja) 2025-07-18

Family

ID=76992067

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022544309A Active JP7710450B2 (ja) 2020-01-23 2021-01-22 Ｆｃ変異を有するヘテロダイマータンパク質
JP2025114854A Pending JP2025160226A (ja) 2020-01-23 2025-07-08 Ｆｃ変異を有するヘテロダイマータンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025114854A Pending JP2025160226A (ja) 2020-01-23 2025-07-08 Ｆｃ変異を有するヘテロダイマータンパク質

Country Status (11)

Country Link
US (1) US20230124669A1 (https=)
EP (1) EP4093778A4 (https=)
JP (2) JP7710450B2 (https=)
KR (1) KR20220145833A (https=)
CN (1) CN115279796A (https=)
AU (1) AU2021210482A1 (https=)
BR (1) BR112022014574A2 (https=)
CA (1) CA3165045A1 (https=)
IL (1) IL294878A (https=)
MX (1) MX2022009101A (https=)
WO (1) WO2021148006A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022170619A1 (en) * 2021-02-11 2022-08-18 Adagene Pte. Ltd. Anti-cd3 antibodies and methods of use thereof
US12441816B2 (en) 2021-09-21 2025-10-14 Qilu Puget Sound Biotherapeutics Corporation Heterodimeric Fc for making fusion proteins and bispecific antibodies
US20250333539A1 (en) * 2022-03-23 2025-10-30 Cytomx Therapeutics, Inc. Activatable antigen-binding protein constructs and uses of the same
WO2023193239A1 (en) 2022-04-08 2023-10-12 Peter Peizhi Luo Anti-cd28 antibodies and methods of use thereof
CN121666401A (zh) * 2023-07-10 2026-03-13 瑞泽恩制药公司 双特异性PD-L1x4-1BB抗体及其使用方法
TW202528360A (zh) * 2023-11-20 2025-07-16 大陸商江蘇恆瑞醫藥股份有限公司 藉由重組反應製備異源多聚體的方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1791565T3 (en) * 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
US8054928B2 (en) * 2005-11-14 2011-11-08 Ati Technologies, Inc. Programmable preamble system and method
RU2636046C2 (ru) * 2009-01-12 2017-11-17 Сайтомкс Терапьютикс, Инк Композиции модифицированных антител, способы их получения и применения
WO2011028952A1 (en) * 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CA2785907A1 (en) * 2009-12-29 2011-07-28 Emergent Product Development Seattle, Llc Ron binding constructs and methods of use thereof
EP2576621B1 (en) * 2010-05-27 2019-04-10 Genmab A/S Monoclonal antibodies against her2
SG11201401422VA (en) * 2011-10-27 2014-09-26 Genmab As Production of heterodimeric proteins
WO2013118722A1 (ja) * 2012-02-06 2013-08-15 トヨタ自動車株式会社 硫化物固体電解質材料、電池および硫化物固体電解質材料の製造方法
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
JP6594855B2 (ja) * 2013-03-15 2019-10-23 ゼンコア インコーポレイテッド ヘテロ二量体タンパク質
JP2016538275A (ja) * 2013-11-04 2016-12-08 グレンマーク ファーマシューティカルズ， エセ．アー． Ｔ細胞再標的化ヘテロ二量体免疫グロブリン（ｈｅｔｅｒｏ−ｄｉｍｅｒｉｃ ｉｍｍｕｎｏｇｌｏｂｕｌｉｎ）の製造
US20160176969A1 (en) * 2014-11-26 2016-06-23 Xencor, Inc. Heterodimeric antibodies including binding to cd8
EP3227332B1 (en) * 2014-12-03 2019-11-06 F.Hoffmann-La Roche Ag Multispecific antibodies
CN107408987B (zh) * 2015-03-20 2020-03-17 日本电气株式会社 可插拔光模块、光通信系统和可插拔光模块控制方法
CN106883297B (zh) * 2015-12-16 2019-12-13 苏州康宁杰瑞生物科技有限公司 基于ch3结构域的异二聚体分子、其制备方法及用途
EP3489262A4 (en) * 2016-07-19 2020-07-08 Ibentrus, Inc. BISPECIFIC PROTEINS AND PROCESSES FOR THEIR PREPARATION
WO2019014912A1 (zh) * 2017-07-21 2019-01-24 赵磊 一种异二聚体蛋白及其制备方法
AU2018393111B2 (en) * 2017-12-21 2025-07-10 Amunix Pharmaceuticals, Inc. Release segments and binding compositions comprising same
WO2019148445A1 (en) * 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
TWI798601B (zh) * 2020-11-27 2023-04-11 晶睿通訊股份有限公司 地面起伏偵測方法及其監控攝影機
JP7295438B2 (ja) * 2020-11-30 2023-06-21 日亜化学工業株式会社 面状光源
WO2023193239A1 (en) * 2022-04-08 2023-10-12 Peter Peizhi Luo Anti-cd28 antibodies and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2023511376A5 (https=)
JP2025160226A5 (https=)
EP2414391B1 (en) Multispecific antibodies comprising full length antibodies and single chain fab fragments
TWI359027B (en) Bivalent, bispecific antibodies
US20220002398A1 (en) ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT
JP2019533441A5 (https=)
AU2015329965A1 (en) Bispecific antibodies against CD3epsilon and ROR1
JP2023516004A5 (https=)
CN106164095A (zh) 多特异性抗体
JP2021507698A5 (https=)
WO2010112194A1 (en) Antigen-binding polypeptides and multispecific antibodies comprising them
JP2023548529A5 (https=)
JP2025508317A5 (https=)
JP2023516941A5 (https=)
WO2025041097A1 (en) Il-18 polypeptides fused to immune cell antigen specific binding polypeptides and uses thereof
WO2018237341A1 (en) A TARGET CELL-DEPENDENT T CELL ENGAGING AND ACTIVATION ASYMMETRIC HETERODIMERIC Fc-ScFv FUSION ANTIBODY FORMAT FOR CANCER THERAPY
JP2026027248A (ja) 抗原結合分子およびその使用
JP2024502095A (ja) 二重または多重特異性抗体｛Ｂｉ ｏｒ Ｍｕｌｔｉ－Ｓｐｅｃｉｆｉｃ Ａｎｔｉｂｏｄｙ｝
JP2021531757A5 (https=)
JP2025511000A5 (https=)
WO2025024780A1 (en) Antibodies that bind gamma-delta t cell receptors for the treatment of cancer
WO2025255480A1 (en) Tetravalent multispecific binding molecules and methods of use thereof
RU2026104696A (ru) Антитела, связывающиеся с cd3
NZ807450A (en) Antibodies binding to gprc5d
JP2022028645A5 (https=)